Hosted on MSN1mon
FDA approves Qelbree label update for ADHD treatmentThe new information in Section 12.2 of the label details Qelbree's partial agonist activity at the serotonin 5-HT2C receptor and its inhibition of the norepinephrine transporter. This multimodal ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback